Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
SARS-CoV-2 anti-spike IgG production and protection from severe respiratory illness should be explored in greater depth after COVID-19 booster vaccination. This longitudinal observational retrospective study investigated the anti-spike IgG response elicited by the first, second and booster doses of BNT162b2 mRNA vaccine in healthcare workers (HCW) at San Martino IRCCS Policlinico Hospital (Genoa) up to the 12 month. Sequential blood sampling was performed at T0 (prior to vaccination), T1 (21 days after the 1 dose of vaccine), T2, T3, T4, T5, T6 (7 days and 1, 3, 6 and 9 months after the 2 dose, respectively), T7 and T8 (1 and 3 months after a booster dose). A SARS-CoV-2 IgG panel (Bio-Rad, Marnes-la-Coquette, France) was used to determine levels of receptor-binding domain (RBD), spike-1 (S1), spike-2 and nucleocapsid structural proteins of SARS-CoV-2. In the 51 HCWs evaluated, seroprevalence was 96% (49/51) at T1 and 100% (51/51) from T2 to T5 for RBD and S1. At T6, only one HCW was negative. T2 [RBD = 2945 (IQR:1693-5364); S1 = 1574 (IQR:833-3256) U/mL], and T7 [RBD = 8204 (IQR:4129-11,912); S1 = 4124 (IQR:2124-6326) U/mL] were characterized by the highest antibody values. Significant humoral increases in RBD and S1 were documented at T7 and T8 compared to T2 and T4, respectively (-value < .001). Following vaccination with BNT162b2 and a booster dose in the 9 month, naïve and healthy subjects show high antibody titers up to 12 months and a protective humoral response against COVID-19 disease lasting up to 20 months after the last booster.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10512804 | PMC |
| http://dx.doi.org/10.1080/21645515.2023.2258632 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Gender and age differences in the risk of allergic reactions following the Pfizer-BioNTech COVID-19 and AstraZeneca vaccine using skin prick test and intradermal test among patients with high risk for hypersensitivity.
Allergol Immunopathol (Madr)
September 2025
Faculty of Medicine, University of Prishtina, University Clinical Center of Kosovo, Prishtina, Republic of Kosovo.
Objective: The aim of this study was to assess the association between allergic reactions after COVID-19 vaccination and the history of high-risk allergy, individual predisposing factors such as age and gender, and COVID-19 vaccine type.
Materials And Methods: This retrospective cohort study included 234 adult patients (18 years old and above) who underwent a COVID-19 vaccine allergy test up until February 2023 in a Clinic of Allergy and Clinical Immunology in the University Clinical Center of Kosovo. All patients suspected of allergy underwent skin testing: SPT (skin prick test) and IDT (intradermal test) using either an mRNA (ribonucleic messenger acid) vaccine (BNT162b2, Pfizer-BioNTech) and/or an adenoviral vector vaccine (AZD1222, AstraZeneca).
Next-Generation Nanoparticle-Enabled mRNA Vaccines in the Treatment of COVID-19.
Crit Rev Ther Drug Carrier Syst
September 2025
The emergence of messenger ribonucleic acid (mRNA) vaccines as an alternative platform to traditional vaccines has been accompanied by advances in nanobiotechnology, which have improved the stability and delivery of these vaccines through novel nanoparticles (NPs). Specifically, the development of NPs for mRNA delivery has facilitated the loading, protection and release of mRNA in the biological microenvironment, leading to the stimulation of mRNA translation for effective intervention strategies. Intriguingly, two mRNA vaccines, BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna), have been permitted for emergency usage authorization to prevent COVID-19 infection by USFDA.
View Article and Find Full Text PDFCellular and humoral immunity following two AZD1222 and two booster vaccinations in hemodialysis patients.
J Microbiol Immunol Infect
August 2025
Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan; Department of Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan. Electronic address:
Background: Dialysis patients are vulnerable to SARS-CoV-2 infection and subsequent complications. However, the vaccine-induced immunity, especially against new variants, following two AZD1222 and two booster doses in hemodialysis patients remain largely unknown.
Methods: In this observational cohort study, we monitored immune responses in 127 hemodialysis patients receiving the 3 and 4th vaccinations until three months after the 4th immunization.
De Novo Immune Induction After COVID-19 Vaccination Under B-Cell Depletion Is Characterized by Robust T-Cellular Immunity in Patients With Inflammatory Central Nervous System Disease.
Brain Behav
September 2025
Department of Transplant and Infection Immunology, Saarland University, Homburg, Germany.
Background: Immune induction under B-cell depletion is complex and far from being fully understood.
Methods: We investigated clinical and immunological responses after dual homologous mRNA vaccination with BNT162b2 and after booster vaccination or infection in 14 B-cell depleted patients with inflammatory central nervous system disease in comparison to 28 healthy controls. Spike-specific IgG were determined using ELISA and neutralizing activity by surrogate assay.
Federated Adaptive Causal Estimation (FACE) of Target Treatment Effects.
J Am Stat Assoc
March 2025
Department of Biostatistics, Harvard University.
Federated learning of causal estimands may greatly improve estimation efficiency by leveraging data from multiple study sites, but robustness to heterogeneity and model misspecifications is vital for ensuring validity. We develop a Federated Adaptive Causal Estimation (FACE) framework to incorporate heterogeneous data from multiple sites to provide treatment effect estimation and inference for a flexibly specified target population of interest. FACE accounts for site-level heterogeneity in the distribution of covariates through density ratio weighting.
View Article and Find Full Text PDF